French biopharmaceutical firm Genkyotex has secured US regulatory approval to conduct a Phase...
Knopp begins study of dexpramipexole in eosinophilic asthma patients
Knopp Biosciences has commenced patient enrolment in a Phase II clinical trial of dexpramipexole for the treatment of moderate-to-severe eosinophilic asthma.
Altavant doses first patient in ELEVATE 1 trial of PAH drug
Altavant Sciences has dosed the first patient in the ELEVATE 1 trial of its lead candidate rodatristat ethyl to treat adults with pulmonary arterial hypertension (PAH).
New respiratory syncytial virus vaccine shows promise in Phase I trial
An experimental vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) to protect against respiratory syncytial virus (RSV) has yielded positive data in a Phase I clinical trial.
Genkyotex to launch Phase II pulmonary fibrosis trial in US
French biopharmaceutical firm Genkyotex has secured US regulatory approval to conduct a Phase II clinical trial of GKT831 for the treatment of idiopathic pulmonary fibrosis (IPF).
Pfizer’s trial of Revatio fails to meet primary endpoint
Pfizer’s Phase III study of intravenous (IV) sildenafil (Revatio) added to inhaled nitric oxide (iNO) to treat newborns with Persistent Pulmonary Hypertension (PPHN) has failed to achieve its primary efficacy endpoint.
Sanofi and Regeneron’s REGN3500 trial meets primary endpoint
Sanofi and Regeneron Pharmaceuticals’ Phase II trial of investigational IL-33 antibody REGN3500 (SAR440340) has met the primary endpoint of improvement in loss of asthma control.
AstraZeneca’s Novel START trial shows Symbicort therapy effectiveness
AstraZeneca's Novel Symbicort Turbuhaler Asthma Reliever Therapy (START) trial has demonstrated the effectiveness of its Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease
Yupelri™ (revefenacin) is a long-acting muscarinic antagonist (LAMA) indicated as a maintenance treatment for chronic obtrusive pulmonary disease (COPD) in adult patients.